SP1 and AL amyloidosis: On the other hand, miR29 can inhibit multiple myeloma cell proliferation via SP1 activation synergizing with bortezomib, causing a potent demethylating effect and inhibiting osteoclastosis and important pathogenetic effects in multiple myeloma patients [20,21,22].